Company Name, Ticker, Industry, else..

Cyclerion Therapeutics Inc (NASDAQ: CYCN)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Cyclerion Therapeutics Inc 's

Name: Cyclerion Therapeutics Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CYCN Sales vs. its Competitors Q2 2026

Comparing the current results to its competitors, Cyclerion Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 7.14 %, recorded in the same quarter.

• List of CYCN Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Cyclerion Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 55.91 %

<< CYCN Stock Performance Comparisons

Cyclerion Therapeutics Inc 's Comment on Competition and Industry Peers

The company has agreed not to compete with Tisento Therapeutics through July 2028 in the development or commercialization of CNS-penetrant sGC stimulators that could compete with purchased programs. Tisento Therapeutics recently initiated dosing of the first patient in its global Phase 2b PRIZM study investigating zagociguat for MELAS. The company expects competition from major and specialty pharmaceutical, biopharmaceutical, device, and biotechnology companies, as well as academic institutions, governmental agencies, and medical research organizations. Several biopharmaceutical companies have therapies in clinical development for treatment-resistant depression (TRD), including psychedelic-related therapies, though none have been approved. The company anticipates competing with the current standard of care and any new therapies that may become available.

<< See the full list of CYCN competitors

*Market share is calculated based on total revenue.

CYCN's Stock Performance relative to its Competitors

Publicly Traded Peers of Cyclerion Therapeutics Inc

Zymeworks Inc
Share Performance

+12.52%

This Quarter

Zymeworks Inc

Profile

Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.

More about Zymeworks Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,961.330 mill.	$ 37.127 mill.	$ -149.992 mill.

Oramed Pharmaceuticals Inc
Share Performance

+97.43%

One Year

Oramed Pharmaceuticals Inc

Profile

Oramed Pharmaceuticals Inc. is a biopharmaceutical company with a business model focused on developing innovative oral drug delivery solutions.

More about Oramed Pharmaceuticals Inc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 201.379 mill.	$ - mill.	$ 174.864 mill.

Nextcure Inc
Share Performance

-11.64%

Over The Past 5 Days

Nextcure Inc

Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 26.602 mill.	$ - mill.	$ -42.748 mill.

Nuvalent Inc
Share Performance

+0.05%

Over The Past 5 Days

Nuvalent Inc

Profile

Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.

More about Nuvalent Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 9,751.979 mill.	$ - mill.	$ -450.074 mill.

Nurix Therapeutics Inc
Share Performance

+30.68%

This Year

Nurix Therapeutics Inc

Profile

Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.

More about Nurix Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,621.592 mill.	$ 36.766 mill.	$ -341.351 mill.

50 more competitors available

Sources: Cyclerion Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Friday, September 18, 2026 5:00 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cyclerion Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.